Discounted Cash Flow (DCF) Analysis Levered
NGM Biopharmaceuticals, Inc. (NGM)
$12.93
+0.26 (+2.05%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 77.14 | 108.66 | 103.54 | 87.37 | 93.35 | 99.74 | 106.56 | 113.85 | 121.64 | 129.97 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -17.41 | -7.60 | -41.17 | -83.50 | -38.48 | -41.12 | -43.93 | -46.94 | -50.15 | -53.58 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -6.42 | -5.84 | -3.49 | -1.88 | -1.68 | -4.19 | -4.48 | -4.79 | -5.12 | -5.47 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -23.83 | -13.44 | -44.66 | -85.37 | -40.17 | -45.31 | -48.41 | -51.72 | -55.26 | -59.04 |
Weighted Average Cost Of Capital
| Share price | $ 12.93 |
|---|---|
| Beta | 1.672 |
| Diluted Shares Outstanding | 77.41 |
| Cost of Debt | |
| Tax Rate | 1.74 |
| After-tax Cost of Debt | -% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 11.509 |
| Total Debt | 15.54 |
| Total Equity | 1,000.90 |
| Total Capital | 1,016.44 |
| Debt Weighting | 1.53 |
| Equity Weighting | 98.47 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 77.14 | 108.66 | 103.54 | 87.37 | 93.35 | 99.74 | 106.56 | 113.85 | 121.64 | 129.97 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -17.41 | -7.60 | -41.17 | -83.50 | -38.48 | -41.12 | -43.93 | -46.94 | -50.15 | -53.58 |
| Capital Expenditure | -6.42 | -5.84 | -3.49 | -1.88 | -1.68 | -4.19 | -4.48 | -4.79 | -5.12 | -5.47 |
| Free Cash Flow | -23.83 | -13.44 | -44.66 | -85.37 | -40.17 | -45.31 | -48.41 | -51.72 | -55.26 | -59.04 |
| WACC | ||||||||||
| PV LFCF | -40.17 | - | - | - | - | - | ||||
| SUM PV LFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | - |
| Free cash flow (t + 1) | -60.23 |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | -136.26 |
| Equity Value | - |
| Shares Outstanding | 77.41 |
| Equity Value Per Share | - |